Radiopharm Theranostics (NASDAQ:RADX) Shares Up 1.1% – Time to Buy?

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) traded up 1.1% during mid-day trading on Friday . The company traded as high as $1.8415 and last traded at $1.7490. Approximately 36,778 shares were traded during trading, a decline of 46% from the average daily volume of 67,978 shares. The stock had previously closed at $1.73.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on RADX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Friday, July 17th. HC Wainwright started coverage on Radiopharm Theranostics in a research report on Thursday, June 4th. They set a “buy” rating and a $6.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Radiopharm Theranostics presently has an average rating of “Hold” and a consensus price target of $11.00.

Radiopharm Theranostics Trading Up 1.1%

The firm has a fifty day simple moving average of $2.83 and a 200-day simple moving average of $3.91.

Radiopharm Theranostics (NASDAQ:RADX) last announced its earnings results on Friday, July 31st. The company reported ($0.81) earnings per share (EPS) for the quarter. The company had revenue of $0.49 million during the quarter. As a group, sell-side analysts forecast that Radiopharm Theranostics Limited – Sponsored ADR will post -3.23 EPS for the current year.

Institutional Investors Weigh In On Radiopharm Theranostics

A hedge fund recently bought a new stake in Radiopharm Theranostics stock. Hsbc Holdings PLC bought a new stake in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 191,624 shares of the company’s stock, valued at approximately $1,007,000. Hsbc Holdings PLC owned 1.62% of Radiopharm Theranostics at the end of the most recent reporting period.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics Limited (NASDAQ: RADX) is an Australian clinical-stage biopharmaceutical company focused on developing radiopharmaceuticals for the diagnosis and treatment of cancer. Its approach combines tumor-targeting molecules with radioactive isotopes to help identify cancer, assess disease progression and deliver targeted radiation to malignant cells.

The company’s pipeline includes investigational diagnostic and therapeutic radiopharmaceuticals based on peptide and antibody platforms.